Abstract
Background A variety of disease-modifying therapies (DMTs) are now available for multiple sclerosis (MS), each with distinct efficacy and risk profiles. However, the clinical course of MS varies significantly both within and between individuals, and the optimal treatment strategy remains uncertain at the group and individual levels. Addressing questions about treatment strategies through traditional randomized controlled trials is unrealistic due to the large sample sizes and high costs required. Instead, large-scale multicenter registries and well-characterized prospective observational cohorts offer a feasible approach to generating meaningful insights. For valid results, such registries and cohorts require harmonization across centers to support comprehensive, standardized, user-friendly data collection while meeting data protection standards and ensuring quality control.
Objective This project aims to establish standardized, nationwide MS data collection in Austria.
Methods The project consists of five key components: i) harmonization of data collection, ii) creation of infrastructure for data sharing, iii) retrospective harmonized data collection (Austrian MS Database, AMSD), iv) prospective harmonized data collection (Austrian MS Cohort, AMSC), and v) aggregated analyses.
Results A comprehensive set of harmonized common data elements (CDE) comprising clinical and paraclinical data was developed and a common data collection infrastructure was generated using the web-based Research, Documentation, and Analysis platform (webRDA), an innovative data capture, processing, and analysis system provided by the Medical University of Vienna offering pseudonymized storage of data supported by a robust permissions system sufficing legal data protection and ethical requirements.
The AMSC is set up as a standardized prospective collection of demographic, clinical, epidemiological, psycho-socio-economic, MRI, and OCT data as well as body fluids.
Conclusion The AMSD and AMSC will facilitate the evidence-based development of prognostic biomarkers, individualized therapy strategies and treatment sequences based on a high-quality, population-based dataset of more than 8,000 people with MS.
Competing Interest Statement
Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Janssen, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis. He serves as an Executive Committee of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Fabian Foettinger: Has received speaker honoraria and travel funding from Novartis. Markus Ponleitner: Has participated in meetings sponsored by, received speaker or consulting honoraria from Amicus and travel funding from Amicus, Merck, Novartis and Sanofi-Genzyme. Klaus Berek: has participated in meetings sponsored by and received travel funding or speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi, and Teva. He is associate editor of Frontiers in Immunology / Neurology, Section Multiple Sclerosis and Neuroimmunology. Franziska Di Pauli: has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, BMS/Celgene, Merck, Novartis, Sanofi, Roche, and Teva. Her institution has received research grants from Roche. Bettina Heschl: has received funding for travel or speaker honoraria from Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Sebastian Wurth: has participated in meetings sponsored by, received honoraria or travel funding from Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Allergan, Ipsen Pharma and Roche. Florian Deisenhammer: has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, BMS, Sanofi, Amgen, Janssen, Laurea Group, Medwhizz, Merck, Novartis Pharma, Neuraxpharm, Roche, Sandoz, and Teva. His institution has received research grants from Biogen, Novartis Pharma, and Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders) and review editor of Frontiers Neurology. Christian Enzinger: has received funding for travel and speaker honoraria from Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Shire and Teva. has received research support from Biogen, Celgene, Merck, and Teva; is serving on scientific advisory boards for Bayer, Biogen, Celgene, Merck, Novartis, Roche and Teva. Thomas Berger: has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, BMS/Celgene, Genesis, GSK, GW/Jazz Pharma, Horizon, Janssen, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva and UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Bayer, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva. Michael Khalil: has received travel funding and speaker honoraria from Bayer, Biogen, Novartis, Merck, Sanofi and Teva and serves on scientific advisory boards for Biogen, BMS/Celgene, Gilead, Merck, Novartis, and Roche. He received research grants from Biogen, Novartis and Teva. Harald Hegen: has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Celgene, Janssen, Merck, Novartis, Sanofi-Genzyme, Siemens and Teva, and received honoraria for consulting Biogen, Celgene, Novartis, Roche, and Teva.
Funding Statement
This project is funded by the Austrian MS Research Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AMSD was approved by the ethics committee of the coordinating center at the Medical University of Vienna (ethical approval number: 1668/2023) as well as the ethics committee of the Medical University of Innsbruck (approval number: 1050/2023) and Graz (approval number: 31-432 ex 18/19). As data are extracted from pre-existing local databases and patient records obtained in routine practice, the need for written informed consent from study participants was waived by the ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
